SAR-bisFAP

SAR-bisFAP is a novel dimeric radiopharmaceutical targeting fibroblast activation protein (FAP), developed by Clarity Pharmaceuticals. It is designed to overcome the low tumor uptake and retention seen with earlier FAP-targeted agents by combining an industry-leading FAP inhibitor (bisFAP) with Clarity’s proprietary SAR chelator technology. This allows for labeling with copper isotopes—copper-64 for diagnostic imaging and copper-67 for targeted radiotherapy of cancers. Preclinical studies have demonstrated that SAR-bisFAP exhibits significantly higher tumor uptake and prolonged retention compared to monomeric FAP agents and first-generation compounds such as FAPI-46, making it a promising candidate for next-generation cancer theranostics[5][6][8].

Brand names

SAR-bisFAP

Other names

64Cu-SAR-bisFAP67Cu-SAR-bisFAP